Our sample of 170 patients was similar to the epidemiologic sample in terms of gender distribution(35.5% men, 64.5% women), age at onset of disease (27.1 Vs 26.0), diagnostic types of MS (RRMS: 85.3% Vs 78.4%), and type of treatment (0.6% of each sample were on glatiramerate acetate, while others were mostly on beta interferon). Here, IFNB1 is linked to myeloid sarcoma.